000963 华东医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入20,965,0662.84%40,623,78337,714,58734,563,30133,683,059
减:营业总成本18,876,7992.35%37,081,91534,568,57031,727,33630,666,230
    其中:营业成本14,109,8041.38%27,461,73225,682,49723,957,37122,550,482
               财务费用23,424-58.06%51,19078,25722,07534,201
               资产减值损失----(6,520)(3,822)(16,908)(4,538)
公允价值变动收益----(13,756)28,469----
投资收益(47,846)-65.05%(219,713)(141,560)(96,312)(27,525)
    其中:对联营企业和合营企业的投资收益(25,256)-79.03%(188,391)(115,619)(53,433)(10,826)
营业利润2,081,11515.72%3,452,9273,061,4542,855,7143,476,575
利润总额2,048,55314.76%3,465,9863,031,1242,827,5353,453,391
减:所得税费用360,3384.36%619,589498,499488,907543,674
净利润1,688,21517.25%2,846,3972,532,6262,338,6282,909,717
减:非控股权益(7,806)-229.42%7,53633,41136,99689,855
股东净利润1,696,02118.29%2,838,8612,499,2142,301,6312,819,861

市场价值指针
每股收益 (元) *0.96818.07%1.6221.4281.3151.612
每股派息 (元) *0.350--0.5800.2900.2900.230
每股净资产 (元) *12.40411.39%11.99710.5929.4758.355
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容